Single-Inhaler Combination Therapy for Asthma
Authors:
- 1 January 2006
- journal article
- review article
- Published by Springer Nature in PharmacoEconomics
- Vol. 24 (10) , 971-988
Abstract
Clinical studies have shown that the combination of an inhaled corticosteroid (ICS) and a long-acting ß2-adrenoceptor agonist (LABA) for patients with asthma is more effective than the use of ICS alone in equivalent or higher doses, as well as the use of other combinations. However, the relatively higher acquisition costs for the combination therapy require assessment of the value of the incremental costs, especially from a societal perspective. This review provides an overall assessment of the cost effectiveness of ICS plus LABA combination therapy for asthma. A systematic literature research was conducted in MEDLINE to identify studies published between January 1994 and September 2005. Cost-effectiveness studies derived from 11 clinical studies were identified. The ICS plus LABA combination was compared with ICS alone in eight studies, ICS plus a leukotriene antagonist in two studies, and a leukotriene antagonist alone in one study. All studies focused on measuring direct medical costs in a total of six different healthcare systems, and three studies conducted sensitivity analyses, including productivity costs. Outcomes were measured in treatment success (changes in lung function), episode-free days, and symptom-free days by evaluating short-term follow-up. The combination of ICS and LABA was found to be more efficacious and cost effective compared with ICS alone or alternative combinations of controller medications. Further considerations for measuring long-term outcomes and dose-response relationships might be required to provide further evidence on the cost effectiveness of combination therapy with ICS plus LABA.Keywords
This publication has 51 references indexed in Scilit:
- The CONCEPT trial: A 1-year, multicenter, randomized,double-blind, double-dummy comparison of a stable dosing regimen of salmeterol/fluticasone propionate with an adjustable maintenance dosing regimen of formoterol/budesonide in adults with persistent asthmaClinical Therapeutics, 2005
- Defining the responder in asthma therapyJournal of Allergy and Clinical Immunology, 2005
- Doubling the dose of budesonide versus maintenance treatment in asthma exacerbationsThorax, 2004
- The effect of adjustable dosing with budesonide/formoterol on health-related quality of life and asthma control compared with fixed dosingCurrent Medical Research and Opinion, 2004
- Addition of montelukast versus double dose of inhaled budesonide in moderate persistent asthmaRespirology, 2004
- An economic evaluation of adjustable and fixed dosing with budesonide/formoterol via a single inhaler in asthma patients: the ASSURE studyCurrent Medical Research and Opinion, 2004
- Cost-effectiveness analysis of early intervention with budesonide in mild persistent asthmaJournal of Allergy and Clinical Immunology, 2003
- Dose-response relation of inhaled fluticasone propionate in adolescents and adults with asthma: meta-analysisCommentary: Dosage needs systematic and critical reviewBMJ, 2001
- Comparison of high dose inhaled steroids, low dose inhaled steroids plus low dose theophylline, and low dose inhaled steroids alone in chronic asthma in general practiceThorax, 2000
- Effect of Inhaled Formoterol and Budesonide on Exacerbations of AsthmaNew England Journal of Medicine, 1997